Prices are updated after-hours

ALTERITY THERAPEUTICS LTD

PRNAF | $0.0002 -90.0% 11450.0% 0

(0.0% 1d) (0.0% 1m) (-95.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (192.0% volume)
Earnings Calendar:
Market Cap: $ 14,901,366
http://www.pranabio.com
Sec Filling | Patents | n/a employees

(AU) Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

parkinson alzheimer neurodegenerative alzheimer’s

add to watch list Paper trade email alert is off

AC Immune SA

ACIU | $2.38 -1.65% -1.68% 190K

Health Technology

(0.0% 1d) (-17.9% 1m) (24.0% 1y) (0.0% 2d) (-1.7% 3d) (0.0% 7d) (-8.9% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 235,379,494
http://www.acimmune.com
Sec Filling | Patents | 132 employees

(CH) AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

neurodegenerative aci-12589 tdp-43 aci-35.030 diagnostics alzheimer aci-7104 treatment

add to watch list Paper trade email alert is off

Alector, Inc.

ALEC | $5.33 3.1% 3.0% 550K

Health Technology

(0.0% 1d) (-10.6% 1m) (-17.5% 1y) (0.0% 2d) (3.3% 3d) (4.9% 7d) (54.75% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 510,343,550
http://www.alector.com
Sec Filling | Patents | 121 employees

(US) Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

neurodegenerative alzheimer parkinson al002 msa treatment alzheimer’s

add to watch list Paper trade email alert is off

Alkermes plc

ALKS | $24.26 0.79% 0.78% 1.2M

Health Technology

(0.0% 1d) (-11.2% 1m) (-20.5% 1y) (0.0% 2d) (0.8% 3d) (2.1% 7d) (-27.07% volume)
Earnings Calendar: 2024-02-15
Market Cap: $ 4,104,408,280
http://www.alkermes.com
Sec Filling | Patents | 2235 employees

Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

schizophrenia opioid neurodegenerative urea treatment injection

Drugs

ARISTADA (aripiprazole lauroxil)
ARISTADA INITIO (aripiprazole lauroxil)
VIVITROL (naltrexone)

add to watch list Paper trade email alert is off

Annovis Bio, Inc.

ANVS | $11.88 3.39% 0.0% 230K

Health Technology

(0.0% 1d) (-0.2% 1m) (-19.6% 1y) (0.0% 2d) (3.4% 3d) (20.6% 7d) (-29.44% volume)
Earnings Calendar:
Market Cap: $ 130,814,232
http://www.annovisbio.com
Sec Filling | Patents | 2 employees

(US) Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.

neurodegenerative alzheimer parkinson alzheimer’s

add to watch list Paper trade email alert is off

Alterity Therapeutics Limited

ATHE | $2.14 0.47% 0.47% 32K

Health Technology

(0.0% 1d) (24.6% 1m) (-24.8% 1y) (0.0% 2d) (0.0% 3d) (-0.5% 7d) (-24.09% volume)
Earnings Calendar:
Market Cap: $ 18,682,264
http://www.pranabio.com
Sec Filling | Patents | 12 employees

(AU) Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

neurodegenerative alzheimer parkinson ath434 msa multiple system atroph α-synuclein alzheimer’s

add to watch list Paper trade email alert is off

Anavex Life Sciences Corp.

AVXL | $3.68 0.0% 1.4M

Health Technology

(0.0% 1d) (-18.5% 1m) (-52.3% 1y) (0.0% 2d) (0.8% 3d) (-8.8% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-06
Market Cap: $ 302,174,040
http://www.anavex.com
Sec Filling | Patents | 16 employees

(US) Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

neurodegenerative alzheimer nervous system parkinson treatment alzheimer’s

add to watch list Paper trade email alert is off

Biogen Inc.

BIIB | $193.18 -0.48% -0.48% 1.4M

Health Technology

(0.0% 1d) (-10.8% 1m) (-31.6% 1y) (0.0% 2d) (-0.5% 3d) (-0.6% 7d) (30.56% volume)
Earnings Calendar: 2024-02-13
Market Cap: $ 28,080,798,958
http://www.biogen.com
Sec Filling | Patents | 7400 employees

(US) Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

sclerosis neurodegenerative multiple sclerosis neurological treatment

Drugs

ALPROLIX (Coagulation Factor IX (Recombinant), Fc Fusion Protein)
AVONEX (interferon beta-1a)
Plegridy (peginterferon beta-1a)
Plegridy Pen (peginterferon beta-1a)
Spinraza (Nusinersen)
Tecfidera (dimethyl fumarate)
TECFIDERA (dimethyl fumarate)
TYSABRI (natalizumab)
Vumerity (diroximel fumarate)

add to watch list Paper trade email alert is off

Denali Therapeutics Inc.

DNLI | $16.11 0.75% 0.74% 1.1M

Health Technology

(0.0% 1d) (-18.9% 1m) (-32.6% 1y) (0.0% 2d) (0.8% 3d) (0.7% 7d) (-64.67% volume)
Earnings Calendar: 2023-11-02
Market Cap: $ 2,296,311,812
http://www.denalitherapeutics.com
Sec Filling | Patents | 261 employees

(US) Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

neurodegenerative

add to watch list Paper trade email alert is off

Intra-Cellular Therapies Inc.

ITCI | $73.96 -0.78% -0.78% 830K

Health Technology

(0.0% 1d) (8.9% 1m) (21.7% 1y) (0.0% 2d) (-0.7% 3d) (-0.3% 7d) (-57.12% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 7,159,859,846
http://www.intracellulartherapies.com
Sec Filling | Patents | 330 employees

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.

neurodegenerative schizophrenia glass alzheimer heavy drug nervous system neuropsychiatric molecule drugs neurological msa treatment alzheimer’s

add to watch list Paper trade email alert is off

NeuroBo Pharmaceuticals, Inc.

NRBO | $3.05 -2.24% -2.3% 42K

Health Technology

(0.0% 1d) (-31.1% 1m) (348.1% 1y) (0.0% 2d) (-3.2% 3d) (-10.4% 7d) (80.4% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 14,963,398
http://www.neurobopharma.com
Sec Filling | Patents | 12 employees

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat neurodegenerative disorders. The company was founded on October 30, 2014 and is headquartered in Boston, MA.

neurodegenerative 3d

add to watch list Paper trade email alert is off

Neurotrope, Inc.

NTRP | $2.9302 -10.93% 2.3K

Health Technology

(0.0% 1d) (-33.3% 1m) (-35.1% 1y) (0.0% 2d) (-2.4% 3d) (5.1% 7d) (60.56% volume)
Earnings Calendar:
Market Cap: $ 2,286,795
http://www.neurotropebioscience.com
Sec Filling | Patents | 7 employees

Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY.

neurodegenerative alzheimer treatment alzheimer’s

add to watch list Paper trade email alert is off

Orgenesis Inc.

ORGS | $0.5099 0.53% 0.53% 18K

Health Technology

(0.0% 1d) (-42.2% 1m) (-51.4% 1y) (0.0% 2d) (2.0% 3d) (4.0% 7d) (-16.39% volume)
Earnings Calendar: 2024-04-15
Market Cap: $ 17,509,345
http://www.orgenesis.com
Sec Filling | Patents | 309 employees

(United States) Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment through MaSTherCell, comprises of services from cell therapy development through cell therapy manufacturing for and companies that provide end-to-end solution. The POC segment provides multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

gene therapies immunotherapy neurodegenerative t-cell metabolic ceiling

add to watch list Paper trade email alert is off

Vaccinex, Inc.

VCNX | $4.94 -2.76% 7.4K

Health Technology

(0.0% 1d) (-36.0% 1m) (1189.7% 1y) (0.0% 2d) (0.4% 3d) (3.3% 7d) (26.19% volume)
Earnings Calendar:
Market Cap: $ 6,084,114
http://www.vaccinex.com
Sec Filling | Patents | 49 employees

Vaccinex, Inc. is a clinical-stage biotechnology company, which engages in the development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses in the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington’s disease. Its products pipeline includes SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.

alzheimer huntington neurodegenerative neuroinflammatory cancer lung cancer antibody autoimmunity t-cell lungs treatment ceiling

add to watch list Paper trade email alert is off